Abstract:Metal-based complexes have occupied a pioneering niche in the treatment of many chronic diseases, including various types of cancers. Despite the phenomenal success of cisplatin for the treatment of many solid malignancies, a limited number of metallo-drugs are in clinical use against cancer chemotherapy till date. While many other prominent platinum and non‑platinum- based metallo-drugs (e.g. NAMI-A, KP1019, carboplatin, oxaliplatin, titanocene dichloride, casiopeinas® etc) have entered clinical trials, many have failed at later stages of R&D due to deleterious toxic effects, intrinsic resistance and poor pharmacokinetic response and low therapeutic efficacy. Nonetheless, research in the area of medicinal inorganic chemistry has been increasing exponentially over the years, employing novel target based drug design strategies aimed at improving pharmacological outcomes and at the same time mitigating the side-effects of these drug entities. Over the last few decades, natural products became one of the key structural motifs in the anticancer drug development. Many eminent researchers in the area of medicinal chemistry are devoted to develop new 3d-transition metal-based anticancer drugs/repurpose the existing bioactive compounds derived from myriad pharmacophores such as coumarins, flavonoids, chromones, alkaloids etc. Metal complexes of natural alkaloids and their analogs such as luotonin A, jatrorrhizine, berberine, oxoaporphine, 8-oxychinoline etc. have gained prominence in the anticancer drug development process as the naturally occurring alkaloids can be anti-proliferative, induce apoptosis and exhibit inhibition of angiogenesis with better healing effect. While some of them are inhibitors of ERK signal-regulated kinases, others show activity based on cyclooxygenases-2 (COX-2) and telomerase inhibition. However, the targets of these alkaloid complexes are still unclear, though it is well-established that they demonstrate anticancer potency by interfering with multiple pathways of tumorigenesis and tumor progression both in vitro and in vivo. Over the last decade, many significant advances have been made towards the development of natural alkaloid-based metallo-drug therapeutics for intervention in cancer chemotherapy that have been summarized below and reviewed in this article.

Tailored Metal-Based Catalysts: A New Platform for Targeted Anticancer Therapies

Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

Metal-Based Catalytic Drug Development for Next-Generation Cancer Therapy

Transitional Metal-Based Noncatalytic Medicine For Tumor Therapy

Metal-Polymer Nanoconjugates Application in Cancer Imaging and Therapy

Metal-Based Nanocatalyst for Combined Cancer Therapeutics

Metal Complexes of Natural Product Like-compounds with Antitumor Activity.

Metal-based approaches to fight cervical cancer

Challenges for Metals in Medicine: How Nanotechnology May Help To Shape the Future

New use of metals as nanosized radioenhancers

Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects

Two-Dimensional Nanomaterial-based catalytic Medicine: Theories, advanced catalyst and system design

Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications

Metal-Organic Frameworks Applications in Synergistic Cancer Photo-Immunotherapy

Homo and heterometallic ruthenium and platinum complexes with multiple targets for therapeutic applications: a review

Metal-based nanoparticle in cancer treatment: lessons learned and challenges

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Nanoscaled metal-organic frameworks: charting a transformative path for cancer therapeutics and beyond

Transition metal complexes as photosensitizers for integrated cancer theranostic applications

Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship